GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small ...

Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

About 40 customers of the Mt. Gilead-Improve Water Association in Columbia were put on a boil-water notice Sunday ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...

This was the stock's second consecutive day of gains.

US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional ...